Jeuveau
Jeuveau is the U.S.-market brand for prabotulinumtoxinA-xvfs, a botulinum toxin type A product manufactured by Daewoong Pharmaceutical and commercialized in the United States by Evolus. In the United States, Jeuveau interpretation should stay anchored to the Jeuveau prescribing information rather than to Nabota or other regional names.
Jeuveau matters because it links Korean toxin manufacturing, U.S. aesthetic commercialization, and the competitive expansion of type A brands beyond the older Botox, Dysport, and Xeomin reference set.
Product Identity
Section titled “Product Identity”| Field | Reference point |
|---|---|
| U.S. brand | Jeuveau |
| Nonproprietary name | PrabotulinumtoxinA-xvfs |
| Toxin type | Botulinum toxin type A |
| Manufacturing / company context | Daewoong Pharmaceutical manufacturing; U.S. commercialization through Evolus |
| Related names | Nabota; Nuceiva in selected markets |
| Comparison anchors | Botox, Dysport, Xeomin, Letybo |
Label Context
Section titled “Label Context”The U.S. prescribing information lists Jeuveau for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
That label anchor is narrow and product-specific. Nabota, Jeuveau, Nuceiva, and other regional naming contexts should not be treated as one universal approval profile.
Market Interpretation
Section titled “Market Interpretation”Jeuveau is often discussed as a newer aesthetic-market peer to Botox, Dysport, Xeomin, Daxxify, and Letybo. The comparison is useful at the market level, but it should not become a conversion chart or a ranking claim.
The Daewoong / Nabota connection also makes Jeuveau important to company-level interpretation. It sits near Hugel and Medytox in the Korean manufacturer graph, while its U.S. label and commercialization pathway are distinct.
Legal and Commercial Context
Section titled “Legal and Commercial Context”Daewoong, Evolus, Medytox, and AbbVie / Allergan have been connected through well-known U.S. trade-secret and settlement history. That history shaped market access and company relationships. It does not establish that one botulinum toxin product is clinically superior, safer, longer-lasting, or unit-equivalent to another.